James Chui - 21 Jun 2022 Form 4 Insider Report for Vaxxinity, Inc.

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
23 Jun 2022, 19:59:58 UTC
Prior SEC filing
06 Jan 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Rene Paula Molina, attorney-in-fact for James Chui

Key filing fact

James Chui filed Form 4 for Vaxxinity, Inc. on 23 Jun 2022.

Key facts

  • This page summarizes James Chui's Form 4 filing for Vaxxinity, Inc..
  • 1 reported transaction and 2 derivative rows are listed below.
  • Accepted by SEC: 23 Jun 2022, 19:59.

Change

  • Previous filing in this sequence was filed on 06 Jan 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VAXX holding

Class A common stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
14,000
Date
21 Jun 2022
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VAXX transaction Derivative

Stock option (right to buy)

Award

Transaction value
$0
Shares
+129,187
Change %
Price
$0.000000
Shares after
129,187
Date
21 Jun 2022
Ownership
Direct
Underlying class
Class A common stock
Underlying amount
129,187
Exercise price
$2.09
Footnotes
F1, F2, F3
VAXX holding Derivative

Stock option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
464,680
Date
21 Jun 2022
Ownership
Direct
Underlying class
Class A common stock
Underlying amount
464,680
Exercise price
$4.12
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation.

Footnote F2

These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the issuer through the vesting date.

Footnote F3

These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .